CCND2-AS1: A potential drug target and biomarker for cancer (G103752584)
CCND2-AS1: A potential drug target and biomarker for cancer
CCND2 (Clinical Cell Line-Derived Neurotrophic Factor-2) is a protein that plays a critical role in the development and maintenance of neural stem cells and their progeny. It is a key regulator of the neural stem cell cycle, and its dysregulation has been implicated in various neurological and psychiatric diseases. The AS1 transcript variant of CCND2 has been identified as a potential drug target and biomarker for cancer.
CCND2-AS1 functions as a negative regulator of the neural stem cell cycle, preventing neurogenic proliferation and promoting cell differentiation. It does this by inhibiting the kinase activity of the nuclear factor of activating T-cell kinases (NFAT), which is critical for the development and maintenance of neural stem cells.
Dysregulation of CCND2 has been implicated in the development and progression of various neurological and psychiatric diseases, including cancer. For example, studies have shown that individuals with neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, have reduced levels of CCND2. Additionally, cancer cells often have increased levels of CCND2, which can contribute to their survival and the development of cancer-induced neurodegeneration.
CCND2-AS1 has also been shown to be involved in the regulation of pain perception and neuroinflammation. For instance, studies have shown that individuals with certain forms of cancer, such as neuroblastoma, have increased levels of CCND2 and are less responsive to pain treatment. This may be because CCND2 helps to regulate the sensitivity of cancer cells to pain signals.
CCND2-AS1 may also be a potential biomarker for cancer, as its levels can be easily measured and correlated with clinical outcomes. For example, studies have shown that the levels of CCND2 have been correlated with the progression of certain cancers, such as lung cancer and breast cancer. This may be because CCND2 plays a role in the regulation of cancer cell survival and the response to chemotherapy.
Targeting CCND2-AS1
The potential drug target for CCND2-AS1 is the neurotrophic factor-2 (NTF2) gene, which encodes a protein that is involved in the regulation of neural stem cells and their progeny. NTF2 is a key regulator of the neural stem cell cycle and has been implicated in various neurological and psychiatric diseases, including cancer.
Targeting NTF2 with small molecules has been shown to be effective in preclinical studies for the treatment of various neurological and psychiatric diseases. For example, studies have shown that inhibition of NTF2 has been effective in treating neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Additionally, inhibition of NTF2 has been shown to be effective in treating certain cancers, such as lung cancer and breast cancer.
CCND2-AS1 may also be a useful target for cancer because its expression is often increased in cancer cells. For example, studies have shown that CCND2-AS1 is often expressed in various types of cancer, including lung cancer, breast cancer, and colon cancer. This makes it a potential target for cancer treatment.
Conclusion
In conclusion, CCND2-AS1 is a protein that has been shown to play a critical role in the development and maintenance of neural stem cells and their progeny. Its dysregulation has been implicated in various neurological and psychiatric diseases, including cancer. The potential drug target for CCND2-AS1 is the neurotrophic factor-2 (NTF2) gene, which encodes a protein that is involved in the regulation of neural stem cells and their progeny. Targeting NTF2 with small molecules has been shown to be effective in preclinical studies for the treatment of various neurological and psychiatric diseases, including cancer. Additionally, CCND2-AS1 may also be a useful target for cancer because its expression is often increased in cancer cells. Further research is needed to determine the effectiveness of CCND2-AS1 as a drug
Protein Name: CCND2 Antisense RNA 1
The "CCND2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCND2-AS1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
CCND3 | CCNDBP1 | CCNE1 | CCNE2 | CCNF | CCNG1 | CCNG2 | CCNH | CCNI | CCNI2 | CCNJ | CCNJL | CCNK | CCNL1 | CCNL2 | CCNO | CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP
